Biotech strategy piece on translating human aging biology into medicines against chronic inflammation. It showcases research approach, trial context and broader aging-drug implications.
Key Takeaways
- Randomized Phase 2 QUELL-CV trial has dosed its first participant
- Approximately 160 adults with obesity, elevated inflammation, and cardiovascular risk will enroll
- Primary endpoint is change in high-sensitivity C-reactive protein to establish dose-response